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THE CLINICAL CHALLENGE:
MULTI-ANTIBIOTIC RESISTANCE IS
NOT A SINGLE EVENT
Antibiotic resistance is recognized globally
as an emerging threat for public health.
The recent World Health Organization
report identifies an array of multidrug
resistant bacterial pathogens as emerging
mortality threats (WHO, 2014). Antibiotic
resistance is not the result of a single
event but the unavoidable outcome of
the vicious evolutionary race between the
pathogens and the host. Humans have
been developing and abusing generations
of potent antibiotics while pathogens have
been orienting their genetic arsenal toward
developing an effective and adaptable
resistance network. Bacterial resistance can
be conventionally classified in three inter-
active layers: (1) the intrinsic, that includes
alterations in the metabolic pathways and
the “classic” antibiotic determinants (per-
meability barrier and efflux, inactivation
and modification of genes, and pathways),
(2) the acquired, which appears through
mutations and horizontal gene transfer
involving antibiotic determinants, and (3)
the phenotypic, where metabolic pathway
changes, often in response to environ-
mental signals, lead to an altered physiol-
ogy contributing to resistant phenotypes
(biofilms, persister cells, quorum sensing).
Multidrug efflux systems aremembrane
transport proteins placed at the epicenter
of intrinsic resistance and have been at
the forefront of research for the last 20
years. They perform essential roles in
cellular metabolism, and differ in mem-
brane topology, energy coupling mech-
anisms and substrate specificities (Dean
et al., 2001; Rees et al., 2009; Fletcher et al.,
2010). Among their potential roles, efflux
pumps are demonstrated to be impor-
tant for detoxification processes of intra-
cellular metabolites, bacterial virulence in
both animal and plant hosts, cell home-
ostasis and intercellular signal trafficking
(Martinez et al., 2009).
Based on their sequence similarity and
structural homology, efflux systems are
classified into six super-families (Dean
et al., 2001). ATP-Binding Cassettes
(ABC), Major Facilitators (MFS),
Resistance-Nodulation cell Division
(RND), Small Multidrug Resistance
(SMR), Multi-Antimicrobial Extrusion
protein family (MATE), and Multidrug
Endosomal Transporters (MET). The
first five families are found mainly in
microorganisms, while the MET family
appears restricted to higher eukaryotes.
Recently, unbiased transcriptomic analyses
of the Acinetobacter baumannii response
to chlorhexidine identified a hypothetical
protein as a new class of drug efflux sys-
tem (Hassan et al., 2013). The clinical role
of efflux systems is the subject of inten-
sive research in emerging threats such
as Methicillin-resistant Staphylococcus
aureus (MRSA) (Lemaire et al., 2007),
Gram-negative pan-drug resistant bacte-
ria (Anyanful et al., 2005; Browning et al.,
2013; Merkx-Jacques et al., 2013) and
Mycobacterium tuberculosis (Holzinger
et al., 2012).
This opinion article emphasizes the
contribution of efflux to multi-antibiotic
resistance, highlights examples where
efflux systems are shaping host-pathogen
interactions in challenging clinical con-
ditions, comments on the advances in
the discovery path of microbial efflux
inhibition, and underlines the need for
highly informative and comprehensive
translational antimicrobial therapeutic
interventions.
THE GAP IN TRANSLATION
Most efflux target based discovery efforts
have severely underestimated the dynamic
nature and phenotypic complexity of
microbial communities in infection sites.
The microbial flora analysis in clinical
human samples is informative for the
importance of microbiome in health and
disease and for the design of host ori-
ented anti-infective approaches as well
as faster and accurate outbreak diag-
nostic countermeasures (Peterson et al.,
2009; Kraal et al., 2014). The coopera-
tive interaction between microbial popu-
lations has a demonstrated amplification
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effect in multi-antibiotic resistance devel-
opment in pathogens (Zhang et al., 2011),
which is consistent with the notion that
pathogenic microbial subpopulations are
not operating independently but as mem-
bers of a poly-microbial biological net-
work. Although the resistancemechanisms
have been largely studied at concentrations
above the minimum inhibitory concentra-
tion (MIC), there is evidence that when
antibiotics (i.e., lantibiotics) interfere with
quorum sensing lead to altered virulence
expression of the pathogens (Andersson
and Hughes, 2014). This network is
directly affected by efflux with roles that
have not been clearly determined.
The human gut is a classic example
where the overall functionality, expres-
sion levels, and physiological role of
efflux systems remain an unexplored
puzzle. Metagenomic investigations of
the human gut microbiome provide
individual-specific strain patterns for
drug uptake and hold promise for the
development of cross-referenced metage-
nomic databases including efflux system
(Schloissnig et al., 2013). There are
few examples of microbiome reference
species with fully described efflux sys-
tems; among the most prominent are
the RNDs in Bacteroides fragilis (Wexler,
2012). Scattered reports are implicating
tetracycline resistance efflux systems in
Clostridium saccharolyticum as a response
to antibiotic challenge combined with
ribosome protection-type resistance
(Kazimierczak et al., 2008). The prevalence
of tetracycline resistance loci has also been
detected in honeybee gut metagenomes
(Tian et al., 2012) and on swine intesti-
nal viriome (phage metagenomes) (Allen
et al., 2011).
Dormant persister cells and other
factors contributing to antibiotic toler-
ance present an intriguing example for
the necessity of system level approaches
that will guide discovery efforts (Tan
et al., 2007; Schneider and Ayres, 2008).
Persisters are a cell subpopulation con-
tributing to resistance phenomena in
recurrent and chronic infections by escap-
ing bactericidal antibiotic challenge and
host immune responses (Cohen et al.,
2013; Willenborg et al., 2014). It is worth
mentioning that efflux system induction
through oxidative stress (i.e., E. coli, RND
AcrAB-TolC) leads to increased numbers
of multidrug-tolerant persisters (Wu et al.,
2012). Conversely, metabolic signals facil-
itate antibiotic uptake through proton-
motive force generation thus stimulating
persister cell killing (Allison et al., 2011).
Those observations lay the ground for a
new discovery era but need to be aligned
with the information linking microbiome
with drug interactions and should be
translated in association with host tissues
and immunity. Although the majority of
antibiotics used in clinical practice are well
tolerated and generally safe, some of the
adverse effects experienced by a small frac-
tion of patients may be life-threatening
(Dancer, 2004). The microbiota coevolves
with the host and can affect its physiology
and metabolism. In fact, it is suggested to
function as an auxiliary, virtual organ that
cooperates with the host through modula-
tion of metabolic pathways leading to host
side effects (Cryan and Dinan, 2012). The
gastrointestinal antibiotic side effects rep-
resent the most frequent disturbances due
to the toxicity on the extremely diverse
bowel flora (Cunha, 2001).
Host tissue effects or systemic adap-
tive and innate immunity triggers are
harder to map and detect. Treatment with
antibiotics results in reduced diversity of
the human microbiome. It is suggested
that the adverse effects (blood dyscrasias,
events in the central nervous system,
drug-induced fever, arrhythmias and elec-
trolyte disorders) are triggered by the host
microbiota (Zeissig and Blumberg, 2014).
Intriguingly, the gut microbiota and pro-
biotic agents act on the levels of circulat-
ing cytokines also affecting brain function,
through endocrine (catecholamines) and
immune (cytokines) pathways known to
participate in the brain-microbiota inter-
play. Additionally, the gut microbiota is
strongly implicated in the hypothalamus–
pituitary–adrenal axis which is regulated
by cortisol secretion leading to the acti-
vation of the immune cells (Cryan and
Dinan, 2012).
A microbial efflux specific example in
direct connection with the immune sys-
tem is related with antimicrobial peptides
(AMPs). AMPs are an integral part of the
innate immune system protecting a host
from invading pathogens (Brogden, 2005;
Nguyen et al., 2011). Cationic AMPs are
considered as alternatives for antibiotics
due to their broad antimicrobial activity.
Antitumor activity has also been reported
for AMPs (Reddy et al., 2004; Hoskin
and Ramamoorthy, 2008). Both ABCs and
RNDs have been associated with resis-
tance mechanisms to AMPs. It is suggested
that ABCs are importing AMPs whereas
RNDs are exporting them (Nikaido, 1996;
Guilhelmelli et al., 2013) but a clear pat-
tern of this involvement has not been
demonstrated.
TARGET-BASED MICROBIAL EFFLUX
INHIBITION
The discovery of small molecule Efflux
Pump Inhibitors (EPIs) has been a rapidly
expanding discipline. Conventional wis-
dom, the available discovery tools and
the clinical necessity for alternative thera-
peutic strategies have pinpointed specific
transporter families as targets for efflux
inhibition. The most classic examples
include the RNDs in Gram-negative bacte-
ria and the prominent ABCs in pathogenic
fungi and cancer cells. There is substan-
tial progress in the identification of lead
chemotypes with EPI properties, but the
inherited transporter promiscuity requires
an informative translational strategy to
define the principles of the interaction
with the host. The pivotal role of efflux
systems has been shown by advances in
cell physiology and host-based transporter
oriented studies. Recent identification of
transporters with designated novel roles
directly implicated in pathogenicity and
cancer is reshaping conventional views and
approaches for efflux inhibition. Several
promising narrow- and broad-spectrum
microbial EPIs have been characterized,
but they did not result in a clinically
useful countermeasure (Lomovskaya and
Bostian, 2006; Kourtesi et al., 2013). In few
occasions, molecules that enhance antibi-
otic activity and reduce in vitro resis-
tance have been identified in successful
preclinical development studies (Hirakata
et al., 2009), hence there are currently
three generations of inhibitors in mam-
malian systems that have failed in different
stages of the clinical development pipeline
(Palmeira et al., 2012).
The EPI development path may be
hindered by the manipulation of efflux
systems which can cause unexpected tox-
icity due to the multitude of physiologi-
cal roles transporters play in human cells.
Target bacteria seem to respond to clinical
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challenge with EPIs through decreasing
their efficacy by developing resistance
mutations (Ahmed et al., 1993; Klyachko
et al., 1997). The threat of cross-resistance
to different antibiotics elevates the com-
plexity of EPI discovery ventures.
The well-studied non-vertebrate hosts
(the nematode Caenorhabditis elegans,
the great wax moth Galleria mellonella, the
fruit fly Drosophilla melanogaster, and the
zebrafish Danio rerio) have been used to
profile efflux based microbial virulence as
well as to develop tractable, whole-animal
antimicrobial screens (Apidianakis et al.,
2007, 2011; Fuchs et al., 2010). C. ele-
gans was used to assess the fitness of
in vitro selected Pseudomonas aerugi-
nosa MexAB-OprM (nalB) and MexCD-
OprJ (nfxB) multidrug resistant mutants
(Sánchez et al., 2002) and to confirm
that overproduction of MexEF-OprN does
not impair P. aeruginosa fitness in com-
petition tests, but resulted in specific
changes in bacterial regulatory networks
(Olivares et al., 2012). Burkholderia pseu-
domallei can cause “disease-like” symp-
toms and kill the nematode but this killing
mechanism is not related to efflux sys-
tems that pump out either aminogly-
cosides or macrolides (O’Quinn et al.,
2001). A direct correlation between efflux
mediated multidrug resistance and vir-
ulence was observed in Klebsiella pneu-
moniae when an array of antimicrobials
was profiled in a C. elegans infection
model (Bialek et al., 2010). Finally, the
design of host-pathogen studies explor-
ing the ability of efflux to interfere with
FIGURE 1 | The microbial effluxome.
virulence determinants appears promis-
ing but not informative, as observational
results vary.
TOWARD REALISTIC EFFLUX
DISCOVERY TOOLS
The need to protect a cell from amphi-
pathic cations has evolved in different
families of efflux systems across differ-
ent organisms despite a lack of overall
molecular homology or similarity in their
mechanism of action. Thus, the RND
super-family has a broad substrate spec-
trum, also found in ABC-transporters,
including apart from antibiotics, amphi-
pathic cations, biocides, dyes, and steroid
hormones (Elkins and Nikaido, 2002;
Lage, 2003; Elkins and Mullis, 2006).
Plants have been identified as sources
of natural efflux substrates and inhibitors
(Tegos, 2006). Disabling RNDs in plant
and human bacterial pathogens led to a
striking increase in antimicrobial activ-
ity (Tegos et al., 2002). As RNDs have
a fundamental role in allowing bacteria
to survive in their ecological niche, many
host-derived compounds have been iden-
tified as potential substrates in humans,
animals and plants (Piddock, 2006). In this
context, it is important to highlight studies
employing metabolomics to identify host-
derived ABC efflux substrates in human
fluids (Krumpochova et al., 2012; van de
Wetering and Sapthu, 2012).
The major limitation in defining the
microbial effluxome (the microbial efflux
system substrate profile in context with the
host physiology and pathology, Figure 1)
is the elusive character of the “fingerprint”
of the natural, host-derived microbial
efflux substrates. This gap prevents any
comprehensive discovery EPI effort and
underlines the need for the design, valida-
tion and translation of highly informative
efflux systems and substrate analyses.
Which factors will determine the effec-
tiveness of efflux based anti-infective
strategies? Are there any competitive ben-
efits in the development of host-based
instead of pathogen-based discovery appli-
cations? The systems-based computational
bio-informatics and chemo-informatics
tools appear as the appropriate stepping
stone in the discovery process. Mapping
of genomes and proteomes have been
advancing at full speed, but without
advanced mining and current laborious
development it will not provide suffi-
cient clarity for the importance of efflux
systems in microbial networks behaviors,
and identification of transporter roles
within the context of the microbiome and
infection.
Two currently available advanced efflux
tools are (1) The TransportDB, a com-
prehensive database of cytoplasmic mem-
brane transporters and outer membrane
channels in organisms with complete
genome sequences (Ren et al., 2007).
The database is annotated with functional
transporter classification, web interfaces
for easy access, query, and data download.
Additionally, TransportDB allows compar-
ative phylogenetic and substrate speci-
ficity analysis. (2) The Transporter-ligand
interactome (TLI) is a knowledge min-
ing tool built on the top of a chemo-
informatics database that is used to collect,
select, curate, organize, analyze, and build
models as well as to distribute screen-
ing results and published bioactivity data
related to fungal and mammalian ABC
transporters. The TLI system provides the
ability to interactively query and orga-
nize the collection of substrates, inhibitors,
their associated assays and chemical struc-
tural features (Tegos et al., 2014).
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